TrialDiabetes care2012

Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.

Richard E Pratley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.